Cargando…

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

BACKGROUND: The aim of this study was to assess radiomics features on pre-treatment [(18)F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC underwent [(18)F]FDG PET/computed tomo...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Helden, E. J., Vacher, Y. J. L., van Wieringen, W. N., van Velden, F. H. P., Verheul, H. M. W., Hoekstra, O. S., Boellaard, R., Menke-van der Houven van Oordt, C. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208805/ https://www.ncbi.nlm.nih.gov/pubmed/30094460 http://dx.doi.org/10.1007/s00259-018-4100-6

Ejemplares similares

Early (18)F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
por: van Helden, Erik J., et al.
Publicado: (2016)

Diagnostic Performance of [(18)F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
por: Iqbal, Ramsha, et al.
Publicado: (2021)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

(18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2021)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation
por: van Velden, Floris H. P., et al.
Publicado: (2016)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Partial volume correction strategies for quantitative FDG PET in oncology
por: Hoetjes, Nikie J., et al.
Publicado: (2010)

The Influence of the Exclusion of Central Necrosis on [(18)F]FDG PET Radiomic Analysis
por: Noortman, Wyanne A., et al.
Publicado: (2021)

Impact of [(18)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology
por: Cheebsumon, Patsuree, et al.
Publicado: (2011)

Optimal imaging time points considering accuracy and precision of Patlak linearization for (89)Zr-immuno-PET: a simulation study
por: Wijngaarden, Jessica E., et al.
Publicado: (2022)

[(18)F]FDG-PET/CT radiomics for the identification of genetic clusters in pheochromocytomas and paragangliomas
por: Noortman, Wyanne A., et al.
Publicado: (2022)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Explainable artificial intelligence (XAI) in radiology and nuclear medicine: a literature review
por: de Vries, Bart M., et al.
Publicado: (2023)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body (18)F-Fluorodeoxyglucose and (89)Zr-Rituximab PET Scans
por: de Vries, Bart M., et al.
Publicado: (2022)

Visual and quantitative evaluation of [(18)F]FES and [(18)F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
por: Mammatas, Lemonitsa H., et al.
Publicado: (2020)

[(18)F]FES uptake in the pituitary gland and white matter of the brain
por: Iqbal, R., et al.
Publicado: (2021)

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Quantitative classification and radiomics of [(18)F]FDG-PET/CT in indeterminate thyroid nodules
por: de Koster, Elizabeth J., et al.
Publicado: (2022)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis
por: Leijenaar, Ralph T.H., et al.
Publicado: (2015)

Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
por: van Velden, Floris H. P., et al.
Publicado: (2011)

Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
por: Mammatas, L. H., et al.
Publicado: (2020)

Predictive value of quantitative (18)F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma
por: Martens, Roland M., et al.
Publicado: (2020)

Effects of rigid and non-rigid image registration on test-retest variability of quantitative [(18)F]FDG PET/CT studies
por: van Velden, Floris HP, et al.
Publicado: (2012)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Adding the temporal domain to PET radiomic features
por: Noortman, Wyanne A., et al.
Publicado: (2020)

(18) F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma
por: Jansen, Marc H A, et al.
Publicado: (2014)

Validation of simplified uptake measures against dynamic Patlak K(i) for quantification of lesional (89)Zr-Immuno-PET antibody uptake
por: Wijngaarden, Jessica E., et al.
Publicado: (2023)

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
por: Jager, Agnes, et al.
Publicado: (2020)

Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2019)

Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

Measurement of metabolic tumor volume: static versus dynamic FDG scans
por: Cheebsumon, Patsuree, et al.
Publicado: (2011)

The Value of (18)F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review
por: Bijlstra, Okker D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5gmonpsui6jrsn0prngnqpsrnu